We study the relationship between regulatory regimes and pharmaceutical firms' pricing strategies using a unique policy experiment from Norway, which in 2003 introduced a reference price (RP) system called index pricing for a sub-sample of off-patent pharmaceuticals, replacing the existing price...

Generic competition in the pharmaceutical market is an effective cost-containment mechanism that improves static efficiency and stimulates pharmaceutical innovation. There is no prior study that has empirically analysed the relative delays in adoption of generic competition. This paper aims to...

Understanding how price regulations affect the adoption of new patent-protected pharmaceutical technologies is a crucial question in designing health systems. This paper addresses this question by examining how price expectations shape the probability of launch, controlling for competition,...

Competition law may play an important role in drug pricing control by containing high prices derived from economic violations. Since the use of competition tools is not limited by the TRIPS Agreement or other international binding disciplines, there is ample policy room to explore how countries,...

More than other EU 'Unions', the proposed Health Union requires proper definition because the EU's competences are limited in this domain.

Das Gesundheitswesen hat sich innerhalb weniger Jahre zu einem wichtigen Feld der wirtschaftspolitischen Debatte entwickelt. Dabei greifen zwei Entwicklungslinien ineinander über. Einerseits entwickelt sich das Gesundheitswesen als Ganzes immer mehr zu einer Gesundheitswirtschaft, wo Wachstums-...